Federal Register: FDA · August 31, 2026 · Primary source
Rahim Shafa; Denial of Hearing; Final Debarment Order
Summary
FDA issued a final debarment order permanently barring Rahim Shafa from providing services to any entity with an approved or pending drug application, and debarring him for 20 years from importing or offering drugs for import into the United States. The order follows FDA's denial of Dr. Shafa's hearing request and is grounded in his conviction of multiple federal felonies related to drug regulation under the FD&C Act. The action is a standard FDA debarment proceeding with no direct Medicare/Medicaid billing, AKS, FCA, or behavioral health compliance dimension.
What this may mean
The debarment order bars Dr. Shafa personally from participation in the drug-application and importation process under the FD&C Act; it does not impose obligations on third-party healthcare organizations. Any entity that knowingly employs or contracts with a debarred individual in a covered capacity faces exposure under 21 U.S.C. § 335a. The action has no direct effect on provider reimbursement, fraud-and-abuse statutes, or behavioral health regulation.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- Federal Register: FDA · October 21, 2026Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; AvailabilityScore 51
- Federal Register: FDA · October 16, 2026Electronic Common Technical Document (eCTD); Data Standards; Supporting Forward Compatibility for eCTD 4.0Score 30
- Federal Register: FDA · October 7, 2026Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; CorrectionScore 30
- Federal Register: FDA · October 15, 2026Authorization of Emergency Use for Four Animal Drugs for the Prevention and Treatment of New World Screwworm; AvailabilityScore 28
- Federal Register: FDA · October 9, 2026Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Expanded Access to Investigational Drugs for Treatment UseScore 28
- Federal Register: FDA · October 16, 2026Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and CommentsScore 26